The system potentiated type I IFN secretion, enhanced antigen‐specific CD8+ T cell responses, and significantly suppressed tumor growth in murine models of 4T1 breast cancer and B16‐OVA melanoma.[100e]. This evidence concerns the gene CD8A and breast cancer.